כל המחקרים
פעיל אך לא מגייסתצפיתי

Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients With Homozygous Familial Hypercholesterolemia

This study focuses on people in Europe who have a rare inherited condition called Homozygous Familial Hypercholesterolemia (HoFH). HoFH means you have extremely high cholesterol from birth, which can lead to serious heart problems at a young age. The research aims to understand if a medicine called lomitapide, which is used to lower cholesterol, helps prevent or reduce these heart-related issues. The study will look at the health records of adult patients who have been taking lomitapide for at least a year. Researchers will compare heart problems these patients had in the three years before starting lomitapide with the heart problems they had during the first three years of taking the medicine. This will help doctors learn more about the long-term benefits of lomitapide in real-life situations.

במבט חטוף

סטטוס
פעיל אך לא מגייס
נותן חסות
Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)
יעד הרשמה
73
התחל
09 Sep 2024
השלמה משוערת
01 Feb 2028

על מה המחקר הזה?

This study is about a very specific and rare health condition called Homozygous Familial Hypercholesterolemia, often shortened to HoFH. If you have HoFH, it means your body has extremely high levels of 'bad' cholesterol (LDL cholesterol) right from birth because of a faulty gene you inherited. This high cholesterol can cause serious heart and blood vessel problems, like heart attacks or strokes, much earlier in life than usual.

Doctors are interested in a medicine called lomitapide, which is approved to treat HoFH. This medicine works by helping to lower those very high cholesterol levels. The main goal of this research is to see if taking lomitapide can help reduce the chances of people with HoFH having serious heart-related events. These events are sometimes called 'Major Adverse Cardiovascular Events' or MACE for short, and they include things like heart attacks, strokes, or needing heart surgery.

To figure this out, researchers are looking at the medical records of adults with HoFH who are already taking lomitapide. They will compare a patient's health during the three years before they started taking lomitapide with their health during the first three years they were on the medicine. This helps doctors understand how the medicine works in a real-world setting, rather than in a controlled lab environment. They'll also check other things like how the medicine affects liver health and other cholesterol levels.

נקודות עיקריות

  • This study looks at a rare condition called HoFH.
  • It aims to see if lomitapide helps prevent heart problems in HoFH patients.
  • Researchers will review existing medical records, not conduct new tests.
  • Participation will not change your current medical care.
  • The study helps doctors understand real-world effects of lomitapide.
  • Your health records from before and after starting lomitapide will be used.

מי עשוי להיות זכאי?

To be considered for this study, you must be an adult, aged 18 or older, and have a confirmed diagnosis of Homozygous Familial Hypercholesterolemia (HoFH). It's also important that you have been taking the medicine lomitapide for at least 12 months.

Additionally, the study needs to be able to look back at your health records for the three years before you started taking lomitapide. This helps the researchers compare your health before and after starting the medicine. Finally, you would need to agree to take part in the study by giving your written consent.

You cannot join the study if you received lomitapide in a way that wasn't approved by doctors, or if you were previously involved in other clinical trials for lomitapide. You also can't be taking any experimental drugs that haven't been approved for use yet in your country.

האם מחקר זה יכול להתאים לך?

ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.

  1. האם אתה בן 18 או יותר?
  2. Do you have a diagnosis of HoFH?
  3. Have you been taking lomitapide for at least 12 months?
  4. Can your doctor provide your medical records from the 3 years before you started lomitapide?
  5. Are you willing to provide written permission for your de-identified data to be used?
ענה על כל שאלה כדי לראות את התוצאה שלך.

מה כרוך בהשתתפות?

If you take part in this study, you won't need to change your current treatment plan with lomitapide or attend extra clinic visits specifically for the study. This is an 'observational' study, which means researchers will gather information from your existing medical records from your doctor's office or hospital.

They will look at data collected during your regular check-ups, so there will be no new tests or medications given to you as part of the study. The study involves reviewing information over a long period: the three years before you started lomitapide and the first three years you were taking it. Your doctor will continue to monitor your health and any side effects as part of your standard care.

סיכונים ותועלות פוטנציאליים

Since this is an observational study using existing medical records, there are very few direct risks associated with simply participating. You won't be given any new treatments or asked to do anything different. However, the study involves collecting your health data, which will be handled carefully to protect your privacy. Lomitapide itself can have side effects, including liver-related issues, which your doctor should already be monitoring as part of your ongoing care. A potential benefit of taking part is that the information gathered from your experience, combined with others, could help doctors better understand how lomitapide works in the long term, potentially improving care for future patients with HoFH. Remember, you have the right to withdraw your consent and stop participating at any time without it affecting your medical care.

Locations (30)

  • CHRU Lille - Centre Hospitalier Universitaire de Lille
    מיקוד מאומת
    ליל, צרפת
  • Centre Hospitalier Universitaire de Lyon (CHU Lyon)
    מיקוד מאומת
    ליון, צרפת
  • Hôpital de la Conception - Assistance Publique Hôpitaux de Marseille (AP-HM)
    מיקוד מאומת
    מרסיי, צרפת
  • Hôpital La Pitié Salpêtrière - Groupe Hospitalier "La Pitié Salpêtrière - Charles Foix"
    מיקוד מאומת
    פריז, צרפת
  • Strasbourg University Hospital (CHU Strasbourg)
    מיקוד מאומת
    שטרסבורג, צרפת
  • University General Hospital of Ioannina
    מיקוד מאומת
    Ioannina, Greece
  • METROPOLITAN HOSPITAL, Piraeus
    מיקוד מאומת
    Piraeus, Greece
  • Policlinico di Catanzaro - A.O.U. Mater Domini
    מיקוד מאומת
    Catanzaro, Italy
  • Ospedale Sant'Anna e San Sebastiano
    מיקוד מאומת
    Caserta, Italy
  • Policlinico Federico II di Napoli
    מיקוד מאומת
    נאפולי, איטליה
  • Policlinico Sant'Orsola - Università di Bologna
    מיקוד מאומת
    Bologna, Italy
  • Arcispedale Sant'Anna - Università degli Studi di Ferrara
    מיקוד מאומת
    Ferrara, Italy

שאלות נפוצות

What is HoFH?

HoFH (Homozygous Familial Hypercholesterolemia) is a rare inherited condition that causes extremely high cholesterol levels from birth, increasing the risk of early heart problems.

What is Lomitapide?

Lomitapide is a medicine approved to help lower cholesterol in people with HoFH.

מה אצטרך לעשות אם אצטרף?

You won't have to do anything extra. The study will look at your existing medical records from before and after you started taking lomitapide.

Will I get a new medicine?

No, this study is about how your current lomitapide treatment works. You won't receive any new medications for the study.

האם המידע שלי נשמר פרטי?

Yes, all your personal health information collected for the study will be handled with strict privacy and confidentiality.

כיצד לגלות עוד

תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.

דיון

דיון קהילתי

מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.